NCT04363749View on ClinicalTrials.gov

COVID-19 Infection: Exploration of Respiratory Control Center Abnormalities

NACompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

April 27, 2020

Primary Completion Date

January 11, 2021

Study Completion Date

January 11, 2021

Conditions
Covid19Neurological Complication
Interventions
OTHER

hypoxia : 14.3 and 12.7% FIO2, hypercapnia 7% CO2, inspiratory mechanical constraint

the fraction of inspired oxygen is reduced from \~21% (room air) to 14.3 and 12.7% allowing the SpO2 to decrease to \~75%, rebreathing test allowing the PCO2 to rise to 65 mmHg, inspiratory mechanical constraint with 50 to 75% of maximum inspiratory pressure

Trial Locations (1)

75013

Département R3S, hôpital de la pitié-salpêtrière, Paris

All Listed Sponsors
lead

Assistance Publique - Hôpitaux de Paris

OTHER

NCT04363749 - COVID-19 Infection: Exploration of Respiratory Control Center Abnormalities | Biotech Hunter | Biotech Hunter